The global nucleic acid amplification testing market was valued at USD 6,199.2 million in 2021 and is anticipated to expand at a compound annual growth rate (CAGR) of 12.78% from 2022 to 2030. Increase in demand for the advanced rapid diagnostics and rising R&D investments for the development of novel biotechnological diagnostic techniques are the factors fueling the market growth. In addition, high global prevalence of the communicable diseases and need for the highly efficient testing alternatives for the successful management of disease outbreaks has propelled demand for the several nucleic acid amplification testing technologies. The COVID-19 has increased demand for the rapid and accurate testing methods, such as nucleic acid amplification testing, for detection of the SARS-CoV-2 virus. Key players involved in the market have developed new product offerings, such as isothermal nucleic acid amplification technology-based tests, to meet high demand for the rapid testing and point-of-care testing.
For instance, in March 2020, Abbott Laboratories received Emergency Use Authorization (EUA), for its Abbott ID NOW COVID-19 test which can deliver positive results within five minutes and negative results within 13 minutes. Such strategic initiatives fueled by the pandemic are expected to boost market growth in the near future.
As nucleic acid amplification testing offers the most precise detection of the target entities, the technique is most commonly used for detection of the infectious agents. The technique has also been extensively studied for diagnostic applications in domains such as cancer, personalized medicine, and forensics. As a result, a broad range of applications for nucleic acid amplification testing are expected to boost the market growth during the forecast period.
Emerging infectious diseases, such as the Monkeypox virus, are opening new avenues for market growth and is evident by the launch and regulatory approval of nucleic acid amplification test products for such diseases. For instance, in September 2022, Quest Diagnostics received the U.S. FDA’s Emergency Use Authorization (EUA) for its Quest Monkeypox PCR test launched in July 2022. Similarly, in August 2022, Todos Medical Ltd. commercially launched its Monkey Pox PCR-based test in the U.S. Hence, such novel infections are expected to further expand the market growth.
However, nucleic acid amplification methods, such as polymerase chain reaction (PCR), are severely limited by the requirement of thermal cycling and temperature control instrumentation, which restricts the adoption of PCR technologies in point-of-care applications. This factor can impede the growth of PCR-based technologies and restrict market growth in the near future.
The PCR tests segment recorded the largest market share of 66.68% in 2021. The technology enables rapid and sensitive detection of a broad range of target nucleic acid molecules and can be used for the detection of specific pathogens that may be difficult to culture in vitro. In addition, widespread penetration of PCR technology has enabled applications of the technique for the detection, quantification, and genotyping of a variety of bacteria and viruses from several types of clinical specimens, including plasma, serum, semen, cerebrospinal fluid, and others. As a result, the PCR tests segment is expected to witness significant growth during the forecast period.
The Isothermal Nucleic Acid Amplification Technology (INAAT) tests segment is projected to expand at a rapid CAGR during the forecast period due to the introduction of novel technologies, such as loop-mediated isothermal amplification (LAMP), strand displacement amplification, and recombinase polymerase amplification, among others, that are broadening the scope of the applications for nucleic acid-based test products.
For instance, in June 2022, a research study published in the Analyst Journal demonstrated a new smartphone-integrated technology that can perform rapid Zika virus testing in a single blood drop with the help of the LAMP technology. Such advancements are anticipated to drive the segment and positively affect market growth.
The infectious disease segment held the largest market share of 46.16% in 2021. This can be attributed to the widespread prevalence and rising incidence rate of infectious diseases such as influenza, sexually transmitted infections, and others. The COVID-19 testing sub-segment held the largest share in 2021 within the infectious disease testing segment due to the global presence of the pandemic and the launch of several new PCR tests.
For instance, in October 2020, Euro fins Central Laboratory launched its Empower DX SARS CoV 2 RT PCR test with the option for at-home sampling. Such product launches are expected to increase the market penetration of PCR tests and drive segment growth.
Oncology testing segment is projected to expand at the fastest CAGR during the forecast period due to the rise in R&D interests for the development of novel cancer diagnostic alternatives and rapid progress in cancer research. For instance, in March 2022, researchers from Queen Mary University of London announced the development of the first PCR test for the detection of oral cancer. Such advancements are likely to fuel growth prospects for the nucleic acid amplification testing of other ontological conditions in the near future.
The central and reference laboratories segment dominated the market in 2021 due to its extensive testing portfolio and coverage across multiple healthcare settings. In addition, supportive government initiatives are aiding in the expansion of the testing capacities of such laboratories. For instance, in June 2022, the Department of Health and Human Services (HHS) expanded the Monkeypox testing capacity to five laboratory companies, including Lab corp., Quest Diagnostics, Mayo Clinic Laboratories, Aegis Science, and Sonic Healthcare.
Hospitals segment is expected to grow at the fastest CAGR of 13.44% by 2030. The rise in healthcare expenditure globally and the increasing role of nucleic acid amplification techniques for disease surveillance and prevention of outbreaks are the factors leading to the growth of the segment. Similarly, growth in hospital testing capacities post-COVID-19 and availability of the high throughput testing capabilities can considerably boost the market prospects for nucleic acid amplification testing.
North America accounted for the largest market share 36.96% in 2021 due to the high extent of chronic disease prevalence and the presence of an established research and healthcare infrastructure. Similarly, demand for nucleic acid amplification tests is also driven by the increasing focus on point-of-care diagnostic methods and the high extent of disease prevention measures in the region.
Asia Pacific is expected to grow at the fastest rate during the forecast period due to the existence of a large population and rising focus on the healthcare systems. High incidence of emerging infectious diseases such as Japanese encephalitis, Hendra, and Nipah virus infections can strengthen the market prospects for nucleic acid amplification testing.
The nucleic acid amplification testing market is highly competitive due to the strategic initiatives adopted by emerging and key players. Several new types of nucleic acid amplification tests have been launched in recent years. For instance, in September 2022, My lab Discovery Solutions launched its Patho Detect HPV Detection PCR Test for the detection of human papillomavirus (HPV) in high-risk individuals. Some of the prominent players in global nucleic acid amplification testing market include:
F. Hoffmann-La Roche Ltd
Becton, Dickinson and Company
Danaher Corporation
Abbott Laboratories
Illumina, Inc.
Siemens Healthineers
bioMérieux SA
Novartis AG
Bio-Rad Laboratories, Inc.
Seegene Inc.
Report Attribute |
Details |
Market size value in 2022 |
USD 7.34 billion |
Revenue forecast in 2030 |
USD 19.23 billion |
Growth rate |
CAGR of 12.78% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Type, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Australia; South Korea; Brazil; Mexico; South Africa; Saudi Arabia; UAE |
Key companies profiled |
F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Danaher Corporation; Abbott Laboratories; Illumina, Inc.; Siemens Healthineers; bio Mérieux SA; Novartis AG; Bio-Rad Laboratories, Inc., See gene Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global nucleic acid amplification testing market based on the type, application, end-use, and region:
Type Outlook (Revenue, USD Million, 2018 - 2030)
Polymerase Chain Reaction (PCR) tests
Isothermal Nucleic Acid Amplification Technology (INAAT) tests
Ligase Chain Reaction (LCR) tests
Application Outlook (Revenue, USD Million, 2018 - 2030)
Infectious Disease Testing
COVID-19 testing
Mosquito borne disease testing
Influenza testing
Sexually transmitted infections testing
Hepatitis testing
Tuberculosis testing
Others
Oncology Testing
Genetic & mitochondrial disease testing
Others
End-Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Central and reference laboratories
Others
Regional Outlook (Revenue, USD Million, 2018-2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global nucleic acid amplification testing market size was estimated at USD 6,199.2 million in 2021 and is expected to reach USD 7.34 billion in 2022.
b. The global nucleic acid amplification testing market is expected to grow at a compound annual growth rate of 12.78% from 2022 to 2030 to reach USD 19.23 billion by 2030.
b. North America dominated the nucleic acid amplification testing market with a share of 36.96% in 2021. This is attributable to the increasing extent of healthcare awareness and growth in demand for nucleic acid amplification-based diagnostics to prevent infectious diseases in the region.
b. Some key players operating in the isothermal nucleic acid amplification technology market include F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Danaher Corporation; Abbott Laboratories; Illumina, Inc.; Siemens Healthineers; bioMérieux SA; Novartis AG; Bio-Rad Laboratories, Inc., Seegene Inc.
b. Key factors driving the market growth include increase in demand for advanced rapid testing options and rising R&D investments for the development of novel biotechnological diagnostic techniques.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.